Epidemiology, risk factors and management of cardiovascular diseases in IBD. (Q38275040)

1 September 2017

1 reference

title

Epidemiology, risk factors and management of cardiovascular diseases in IBD. (English)

1 reference

1 September 2017

cardiovascular disease

1 reference

4

Edward V Loftus

1 reference

1 September 2017

Siddharth Singh

1

1 reference

1 September 2017

Iftikhar J Kullo

series ordinal

2

1 reference

1 September 2017

Darrell S Pardi

series ordinal

3

1 reference

1 September 2017

language of work or name

English

0 references

publication date

2 December 2014

1 reference

Nature Reviews Gastroenterology & Hepatology

1 September 2017

1 reference

1 September 2017

12

1 reference

1 September 2017

1

1 reference

1 September 2017

26-35

1 reference

https://scigraph.springernature.com/pub.10.1038/nrgastro.2014.202

1 September 2017

0 references

cites work

Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Venous thromboembolism and atherothrombosis: an integrated approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death--a Danish nationwide cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Inflammatory bowel disease is associated with an increased risk of hospitalization for heart failure: a Danish Nationwide Cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Inflammatory bowel disease is associated with an increased incidence of cardiovascular events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Inflammatory bowel disease is not a risk factor for cardiovascular disease mortality: results from a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Women and ischemic heart disease: evolving knowledge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Gender gap in acute coronary heart disease: Myth or reality?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

The effect of including C-reactive protein in cardiovascular risk prediction models for women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Risk of ischemic stroke in patients with Crohn's disease: a population-based nested case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Inflammation, atherosclerosis, and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Increased carotid intima-media thickness in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Carotid intima-media thickness in patients with inflammatory bowel disease: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Endothelial dysfunction over the course of coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Microvascular function predicts cardiovascular events in primary prevention: long-term results from the Firefighters and Their Endothelium (FATE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Coronary microvascular reactivity to adenosine predicts adverse outcome in women evaluated for suspected ischemia results from the National Heart, Lung and Blood Institute WISE (Women's Ischemia Syndrome Evaluation) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Validated methods for assessment of subclinical atherosclerosis in rheumatology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Evidence of endothelial dysfunction in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Endothelial function and cardiovascular risk in active inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Premature subclinical atherosclerosis in pediatric inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

S100A8 and S100A9 in cardiovascular biology and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Plasma calprotectin predicts mortality in patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Meta-analysis: hyperhomocysteinaemia in inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Plasma total homocysteine in the active stage of ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Homocysteine and vascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Increased levels of lipoprotein (a) in Crohn's disease: a relation to thrombosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

The prognostic power of the NOD2 genotype for complicated Crohn's disease: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Association between NOD2/CARD15 polymorphisms and coronary artery disease: a case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Role of NOD2/CARD15 in coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Platelets in inflammation and atherogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Thromboembolism in inflammatory bowel disease: role of platelets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

No increased risk of myocardial infarction among patients with ulcerative colitis or Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Increased risk for coronary heart disease, asthma, and connective tissue diseases in inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Venous and arterial disease in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Changes in lipid levels with inflammation and therapy in RA: a maturing paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Dyslipidemia and lipoprotein profiles in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Plasma lipids and inflammation in active inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Prediction of Coronary Heart Disease Using Risk Factor Categories

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Inflammatory bowel disease and coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Harmful effects of the azathioprine metabolite 6-mercaptopurine in vascular cells: induction of mineralization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Vascular effects of biologic agents in RA and spondyloarthropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Aspirin in the aetiology of Crohn's disease and ulcerative colitis: a European prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Aspirin, nonsteroidal anti-inflammatory drug use, and risk for Crohn disease and ulcerative colitis: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Prevalence and mechanism of nonsteroidal anti-inflammatory drug-induced clinical relapse in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Lack of efficacy of ridogrel, a thromboxane synthase inhibitor, in a placebo-controlled, double-blind, multi-centre clinical trial in active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: two multicentre, randomized, double-blind studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

The effects of statin therapy on plasma markers of inflammation in patients without vascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Simvastatin inhibits NF-kappaB signaling in intestinal epithelial cells and ameliorates acute murine colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor pravastatin reduces disease activity and inflammation in dextran-sulfate induced colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Statins are associated with reduced use of steroids in inflammatory bowel disease: a retrospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Simvastatin induces apoptosis in human colon cancer cells and in tumor xenografts, and attenuates colitis-associated colon cancer in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Risk of colorectal cancer in self-reported inflammatory bowel disease and modification of risk by statin and NSAID use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Prevention of fibrosis in experimental colitis by captopril: the role of tgf-beta1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Rheumatoid arthritis and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Arterial stiffness is increased in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Increased arterial stiffness in inflammatory bowel diseases is dependent upon inflammation and reduced by immunomodulatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Infliximab is Associated with Improvement in Arterial Stiffness in Patients with Early Rheumatoid Arthritis -- A Randomized Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Cardiovascular death in rheumatoid arthritis: a population-based study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Cardiovascular risk in inflammatory bowel disease: it's a heartache!

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Risk of arterial thrombotic events in inflammatory bowel disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Inflammation and atherosclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

A Quantitative Assessment of Plasma Homocysteine as a Risk Factor for Vascular Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Anti-cardiolipin and anti-beta2-glycoprotein I antibodies in patients with inflammatory bowel disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Platelets circulate in an activated state in inflammatory bowel disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Platelets trigger a CD40-dependent inflammatory response in the microvasculature of inflammatory bowel disease patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Altered lipid, apolipoprotein, and lipoprotein profiles in inflammatory bowel disease: consequences on the cholesterol efflux capacity of serum using Fu5AH cell system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Inhibition of platelet activation by 5-aminosalicylic acid in inflammatory bowel disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Tumour necrosis factor blocking agents and progression of subclinical atherosclerosis in patients with ankylosing spondylitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

The effect of antiplatelet therapy in patients with inflammatory bowel disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Evaluation of the concomitant use of methotrexate and curcumin on Freund's complete adjuvant-induced arthritis and hematological indices in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Simvastatin attenuates intestinal fibrosis independent of the anti-inflammatory effect by promoting fibroblast/myofibroblast apoptosis in the regeneration/healing process from TNBS-induced colitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Conventional risk factors and cardiovascular outcomes of patients with inflammatory bowel disease with confirmed coronary artery disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2014.202

Incidence of arterial cardiovascular events after venous thromboembolism: a systematic review and a meta-analysis.

31 March 2020

1 reference

12 December 2020

Evaluation of anti-inflammatory effect of anti-platelet agent-clopidogrel in experimentally induced inflammatory bowel disease

1 reference

12 December 2020

Increased colonic mucosal angiotensin I and II concentrations in Crohn's colitis

1 reference

12 December 2020

Rosuvastatin, a new HMG-CoA reductase inhibitor, reduces the colonic inflammatory response in dextran sulfate sodium-induced colitis in mice.

1 reference

12 December 2020

10.1038/NRGASTRO.2014.202

Identifiers

DOI

1 reference

Dimensions Publication ID

1 September 2017

0 references

1 reference